NAS:NRCIB (USA) Also trade in: Germany

National Research Corp

$ 53.01 0 (0%)
On watch
Volume: 0 Avg Vol (1m): 0
Market Cap $: 905.94 Mil Enterprise Value $: 941.99 Mil
P/E (TTM): 0.00 P/B: 57.06
Earnings Power Value 9.44
Net Current Asset Value -2.41
Tangible Book -1.52
Projected FCF 10.03
Median P/S Value 3.44
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 6/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 0.07
Cash-To-Debt ranked higher than
65.13% of 261 companies
in the Diagnostics & Research industry.
Industry Max: 32990, Med: 3.52, Min: 0.01
NRCIB: 0.07
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 0.05, Med: 2.01, Max: 10000
Current: 0.07
0.05
10000
Equity-to-Asset 0.22
Equity-to-Asset ranked higher than
66.11% of 239 companies
in the Diagnostics & Research industry.
Industry Max: 0.97, Med: 0.61, Min: -2.81
NRCIB: 0.22
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: 0.18, Med: 0.67, Max: 0.81
Current: 0.22
0.18
0.81
Debt-to-Equity 1.70
Debt-to-Equity ranked higher than
93.29% of 164 companies
in the Diagnostics & Research industry.
Industry Max: 22.86, Med: 0.36, Min: 0.01
NRCIB: 1.7
Ranked among companies with meaningful Debt-to-Equity only.
Debt-to-Equity range over the past 10 years
Min: 0, Med: 0.16, Max: 1.99
Current: 1.7
0
1.99
Debt-to-EBITDA 0.89
Debt-to-EBITDA ranked higher than
99.14% of 116 companies
in the Diagnostics & Research industry.
Industry Max: 77.72, Med: 1.77, Min: 0.03
NRCIB: 0.89
Ranked among companies with meaningful Debt-to-EBITDA only.
Debt-to-EBITDA range over the past 10 years
Min: 0.03, Med: 0.4, Max: 0.91
Current: 0.89
0.03
0.91
Interest Coverage 17.83
Interest Coverage ranked higher than
57.67% of 163 companies
in the Diagnostics & Research industry.
Industry Max: 15605.52, Med: 76.01, Min: 0.54
NRCIB: 17.83
Ranked among companies with meaningful Interest Coverage only.
Interest Coverage range over the past 10 years
Min: 17.83, Med: 52.24, Max: 417.3
Current: 17.83
17.83
417.3
Piotroski F-Score 6
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 7.42
DISTRESS
GREY
SAFE
Beneish M-Score -3.36
Not Manipulator
Manipulator

Profitability & Growth : 5/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % 30.81
Operating Margin ranked higher than
95.04% of 242 companies
in the Diagnostics & Research industry.
Industry Max: 53.36, Med: -0.59, Min: -70300
NRCIB: 30.81
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: 21.86, Med: 26.54, Max: 30.81
Current: 30.81
21.86
30.81
Net Margin % 25.75
Net Margin ranked higher than
92.53% of 241 companies
in the Diagnostics & Research industry.
Industry Max: 41.13, Med: -2.48, Min: -119600
NRCIB: 25.75
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: 13.41, Med: 17.33, Max: 25.75
Current: 25.75
13.41
25.75
ROE % 79.42
ROE ranked higher than
93.80% of 242 companies
in the Diagnostics & Research industry.
Industry Max: 61.7, Med: -6.75, Min: -12038.19
NRCIB: 79.42
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: 18.33, Med: 23.44, Max: 79.42
Current: 79.42
18.33
79.42
ROA % 27.86
ROA ranked higher than
94.27% of 262 companies
in the Diagnostics & Research industry.
Industry Max: 1174.65, Med: -4.54, Min: -1248.4
NRCIB: 27.86
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: 10.1, Med: 14.84, Max: 27.86
Current: 27.86
10.1
27.86
ROC (Joel Greenblatt) % 276.37
ROC (Joel Greenblatt) ranked higher than
98.46% of 259 companies
in the Diagnostics & Research industry.
Industry Max: 17601.65, Med: -9.57, Min: -3842027.78
NRCIB: 276.37
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: 97.03, Med: 220.15, Max: 284.42
Current: 276.37
97.03
284.42
3-Year Total Revenue Growth Rate 5.40
3-Year Revenue Growth Rate ranked higher than
52.20% of 182 companies
in the Diagnostics & Research industry.
Industry Max: 371, Med: 4.8, Min: -100
NRCIB: -30.5
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
N/A
3-Year Total EBITDA Growth Rate 9.60
3-Year EBITDA Growth Rate ranked lower than
53.37% of 178 companies
in the Diagnostics & Research industry.
Industry Max: 141.7, Med: 10.1, Min: -340.1
NRCIB: -27.7
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
N/A
3-Year EPS w/o NRI Growth Rate -100.00
3-Year EPS w/o NRI Growth Rate ranked lower than
50.31% of 163 companies
in the Diagnostics & Research industry.
Industry Max: 138.7, Med: 10.1, Min: -301
NRCIB: -100
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
N/A

» NRCIB's 30-Y Financials

Financials (Next Earnings Date: 2019-08-01 Est.)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:NRCIB

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Medical Diagnostics & Research » Diagnostics & Research    NAICS : 621399    SIC : 8099
Compare NAS:FLDM NAS:LNTH HKSE:01763 OSTO:CEVI SHSE:600055 SZSE:300439 TSE:4282 SZSE:300685 NAS:TWST SHSE:603108 LSE:IDHC XBRU:BCART SZSE:300396 NAS:AXDX NAS:PACB SHSE:603127 BSP:PARD3 NAS:CDNA SHSE:603716 NAS:RDNT
Traded in other countries NR1A.Germany
Address 1245 Q Street, Lincoln, NE, USA, 68508
National Research Corp is a provider of analytics and insights that facilitate measurement and improvement of the patient and employee experience while also increasing patient engagement and customer loyalty for healthcare providers, payers, and other healthcare organizations. The company's portfolio of subscription-based solutions provides actionable information and analysis to healthcare organizations and payers across a range of mission-critical, constituent-related elements, including patient experience and satisfaction, community population health risks, workforce engagement, community perceptions, and physician engagement. The company operates in US and Canada. The maximum revenue derives from the United States.

Ratios

Current vs industry vs history
Price-to-Owner-Earnings 38.61
Price-to-Owner-Earnings ranked higher than
85.53% of 76 companies
in the Diagnostics & Research industry.
Industry Max: 1523.53, Med: 36.75, Min: 4.91
NRCIB: 38.61
Ranked among companies with meaningful Price-to-Owner-Earnings only.
Price-to-Owner-Earnings range over the past 10 years
Min: 1.42, Med: 3.69, Max: 55.74
Current: 38.61
1.42
55.74
PB Ratio 57.06
PB Ratio ranked lower than
89.80% of 245 companies
in the Diagnostics & Research industry.
Industry Max: 270, Med: 4.02, Min: 0.15
NRCIB: 57.06
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 0.42, Med: 1.03, Max: 57.06
Current: 57.06
0.42
57.06
PS Ratio 10.80
PS Ratio ranked higher than
59.13% of 230 companies
in the Diagnostics & Research industry.
Industry Max: 6350, Med: 3.81, Min: 0.07
NRCIB: 10.8
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 0.32, Med: 0.7, Max: 10.8
Current: 10.8
0.32
10.8
Price-to-Free-Cash-Flow 39.18
Price-to-Free-Cash-Flow ranked higher than
85.00% of 80 companies
in the Diagnostics & Research industry.
Industry Max: 1356.19, Med: 29.22, Min: 0.35
NRCIB: 39.18
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
Price-to-Free-Cash-Flow range over the past 10 years
Min: 1.44, Med: 3.52, Max: 39.18
Current: 39.18
1.44
39.18
Price-to-Operating-Cash-Flow 33.34
Price-to-Operating-Cash-Flow ranked higher than
81.44% of 97 companies
in the Diagnostics & Research industry.
Industry Max: 1739.7, Med: 19.94, Min: 0.35
NRCIB: 33.34
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
Price-to-Operating-Cash-Flow range over the past 10 years
Min: 1.23, Med: 3.09, Max: 33.34
Current: 33.34
1.23
33.34
EV-to-EBIT 25.00
EV-to-EBIT ranked higher than
56.78% of 118 companies
in the Diagnostics & Research industry.
Industry Max: 341.21, Med: 25.06, Min: 5.74
NRCIB: 25
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: 1.5, Med: 3.3, Max: 37.9
Current: 25
1.5
37.9
EV-to-EBITDA 21.77
EV-to-EBITDA ranked higher than
50.76% of 132 companies
in the Diagnostics & Research industry.
Industry Max: 486.47, Med: 20.75, Min: 3.94
NRCIB: 21.77
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: 1.2, Med: 2.7, Max: 33.1
Current: 21.77
1.2
33.1
EV-to-Revenue 7.84
EV-to-Revenue ranked lower than
62.81% of 242 companies
in the Diagnostics & Research industry.
Industry Max: 19679, Med: 4.24, Min: 0.09
NRCIB: 7.84
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: 0.4, Med: 0.8, Max: 10.7
Current: 7.84
0.4
10.7
Shiller PE Ratio 17.15
Shiller PE Ratio ranked higher than
94.87% of 39 companies
in the Diagnostics & Research industry.
Industry Max: 459.08, Med: 52.49, Min: 10.19
NRCIB: 17.15
Ranked among companies with meaningful Shiller PE Ratio only.
Shiller PE Ratio range over the past 10 years
Min: 3.47, Med: 6.99, Max: 18.57
Current: 17.15
3.47
18.57
Current Ratio 0.58
Current Ratio ranked lower than
70.00% of 250 companies
in the Diagnostics & Research industry.
Industry Max: 97.84, Med: 2.58, Min: 0.02
NRCIB: 0.58
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 0.49, Med: 1.53, Max: 5.41
Current: 0.58
0.49
5.41
Quick Ratio 0.58
Quick Ratio ranked lower than
64.00% of 250 companies
in the Diagnostics & Research industry.
Industry Max: 97.84, Med: 2.14, Min: 0.02
NRCIB: 0.58
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 0.49, Med: 1.53, Max: 5.41
Current: 0.58
0.49
5.41
Days Sales Outstanding 48.27
Days Sales Outstanding ranked higher than
77.94% of 204 companies
in the Diagnostics & Research industry.
Industry Max: 521.64, Med: 67.51, Min: 1
NRCIB: 48.27
Ranked among companies with meaningful Days Sales Outstanding only.
Days Sales Outstanding range over the past 10 years
Min: 29.97, Med: 39.95, Max: 53.89
Current: 48.27
29.97
53.89
Days Payable 12.06
Days Payable ranked lower than
96.79% of 187 companies
in the Diagnostics & Research industry.
Industry Max: 981.81, Med: 63.34, Min: 1
NRCIB: 12.06
Ranked among companies with meaningful Days Payable only.
Days Payable range over the past 10 years
Min: 3, Med: 6.14, Max: 14.16
Current: 12.06
3
14.16

Dividend & Buy Back

Current vs industry vs history
Dividend Yield % 4.53
Trailing Dividend Yield ranked higher than
95.87% of 121 companies
in the Diagnostics & Research industry.
Industry Max: 10.16, Med: 0.81, Min: 0.07
NRCIB: 4.53
Ranked among companies with meaningful Trailing Dividend Yield only.
Trailing Dividend Yield range over the past 10 years
Min: 0.94, Med: 12.86, Max: 23.19
Current: 4.53
0.94
23.19
Dividend Payout Ratio 0.75
Dividend Payout Ratio ranked higher than
98.57% of 70 companies
in the Diagnostics & Research industry.
Industry Max: 6.35, Med: 0.32, Min: 0.03
NRCIB: 0.75
Ranked among companies with meaningful Dividend Payout Ratio only.
Dividend Payout Ratio range over the past 10 years
Min: 0.14, Med: 0.52, Max: 0.76
Current: 0.75
0.14
0.76
3-Year Dividend Growth Rate (Per Share) -100.00
3-Year Dividend Growth Rate ranked higher than
86.11% of 36 companies
in the Diagnostics & Research industry.
Industry Max: 77.2, Med: 9.9, Min: -100
NRCIB: -100
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
N/A
Forward Dividend Yield % 4.53
Forward Dividend Yield ranked higher than
92.04% of 113 companies
in the Diagnostics & Research industry.
Industry Max: 10.53, Med: 1.1, Min: 0.07
NRCIB: 4.53
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield-on-Cost (5-Year) % 4.53
Yield-on-Cost (5y) ranked higher than
87.32% of 142 companies
in the Diagnostics & Research industry.
Industry Max: 12, Med: 1.41, Min: 0.08
NRCIB: 4.53
Ranked among companies with meaningful Yield-on-Cost (5y) only.
Yield-on-Cost (5y) range over the past 10 years
Min: 0.94, Med: 12.86, Max: 23.19
Current: 4.53
0.94
23.19
3-Year Share Buyback Rate -0.20
3-Year Share Buyback Rate ranked higher than
83.89% of 180 companies
in the Diagnostics & Research industry.
Industry Max: 3.4, Med: -7.9, Min: -1732.6
NRCIB: -0.2
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -93.8, Med: -0.1, Max: 0
Current: -0.2
-93.8
0

Valuation & Return

Current vs industry vs history
Price-to-Projected-FCF 5.29
Price-to-Intrinsic-Value-Projected-FCF ranked higher than
77.33% of 75 companies
in the Diagnostics & Research industry.
Industry Max: 449, Med: 2.41, Min: 0.47
NRCIB: 5.29
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
Price-to-Intrinsic-Value-Projected-FCF range over the past 10 years
Min: 0, Med: 0.28, Max: 5.29
Current: 5.29
0
5.29
Price-to-Median-PS-Value 15.41
Price-to-Median-PS-Value ranked lower than
96.89% of 193 companies
in the Diagnostics & Research industry.
Industry Max: 7.22, Med: 1.01, Min: 0.01
NRCIB: 15.41
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0, Med: 0.76, Max: 15.41
Current: 15.41
0
15.41
Earnings Yield (Joel Greenblatt) % 4.00
Earnings Yield (Greenblatt) ranked higher than
80.75% of 265 companies
in the Diagnostics & Research industry.
Industry Max: 17.42, Med: -0.98, Min: -1428.57
NRCIB: 4
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: 2.6, Med: 30.1, Max: 68.2
Current: 4
2.6
68.2
Forward Rate of Return (Yacktman) % -5.00
Forward Rate of Return ranked lower than
75.71% of 70 companies
in the Diagnostics & Research industry.
Industry Max: 7802.99, Med: 8.45, Min: -35.9
NRCIB: -5
Ranked among companies with meaningful Forward Rate of Return only.
Forward Rate of Return range over the past 10 years
Min: -5, Med: 36.45, Max: 66.3
Current: -5
-5
66.3

More Statistics

Revenue (TTM) (Mil) $ 120.15
EPS (TTM) $ 0
Beta 0
Volatility % 19.66
52-Week Range $ 41.28 - 58.16
Shares Outstanding (Mil) 24.51

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 6
Positive ROA Y
Positive CFROA Y
Higher ROA yoy Y
CFROA > ROA Y
Lower Leverage yoy N
Higher Current Ratio yoy N
Less Shares Outstanding yoy Y
Higher Gross Margin yoy Y
Higher Asset Turnover yoy N